Sugi Predict

Sugi Predict / Targets / SCN2B

SCN2B

Sodium channel regulatory subunit beta-2 · O60939 · SCN2B on Sugi Atlas →

5,926 patent compounds predicted against SCN2B, 4,066 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6840243 SCHEMBL6840243 0.70 13/20
SCHEMBL6840201 SCHEMBL6840201 0.68 11/20
SCHEMBL6840202 SCHEMBL6840202 0.53 11/20
SCHEMBL6840241 SCHEMBL6840241 0.68 10/20
SCHEMBL366784 SCHEMBL366784 0.50 9/20
SCHEMBL2632994 SCHEMBL2632994 0.59 7/20
SCHEMBL2626891 SCHEMBL2626891 0.59 6/20
SCHEMBL3141104 SCHEMBL3141104 0.43 6/20
SCHEMBL3227794 SCHEMBL3227794 0.39 6/20
SCHEMBL366783 SCHEMBL366783 0.48 5/20
SCHEMBL2278495 SCHEMBL2278495 0.41 4/20
SCHEMBL830778 SCHEMBL830778 0.37 4/20
SCHEMBL8859126 SCHEMBL8859126 0.32 4/20
SCHEMBL831663 SCHEMBL831663 0.32 4/20
SCHEMBL678844 SCHEMBL678844 0.53 3/20
SCHEMBL680213 SCHEMBL680213 0.52 3/20
SCHEMBL365341 SCHEMBL365341 0.44 3/20
SCHEMBL3374779 SCHEMBL3374779 0.43 3/20
SCHEMBL3631049 SCHEMBL3631049 0.40 3/20
SCHEMBL831949 SCHEMBL831949 0.38 3/20

Clinical trials — most relevant to SCN2B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations PHASE4COMPLETED
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety PHASE3RECRUITING
Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation PHASE2/PHASE3WITHDRAWN
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome PHASE1/PHASE2COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) PHASE1/PHASE2RECRUITING
Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies PHASE2WITHDRAWN
ST-segment Elevation as an AF Endophenotype nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA) nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy nanCOMPLETED
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom nanRECRUITING
Treatment of Gait Disorders in Children With Dravet Syndrome nanCOMPLETED
Na+ Channel mRNA Regulation in Heart Failure nanCOMPLETED
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients nanCOMPLETED
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A nanCOMPLETED
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation nanRECRUITING
Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome nanCOMPLETED
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation. nanUNKNOWN
fMRI-study in Patients With Small Fiber Neuropathy nanUNKNOWN
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN
Cohort Description of Younger With AV-block nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SCN2B binder may also engage these)

ProteinNameSimilarity
Q864L3 — 1.000 Q864L3 →
P54900 — 0.993 P54900 →
Q56A07 — 0.988 Q56A07 →
Q7M729 — 0.969 Q7M729 →
Q8IWT1 — 0.969 Q8IWT1 →
Q7M730 — 0.967 Q7M730 →
Q96IQ7 — 0.953 Q96IQ7 →
O95297 — 0.952 O95297 →
Q08E08 — 0.949 Q08E08 →
PDCD1LG2 Programmed cell death 1 ligand 2 0.949 landscape →
Q8BHK2 — 0.948 Q8BHK2 →
Q6AYP5 — 0.947 Q6AYP5 →
Q15223 — 0.946 Q15223 →
Q9GL76 — 0.945 Q9GL76 →
Q9BY67 — 0.944 Q9BY67 →
Q8HXJ7 — 0.943 Q8HXJ7 →
Q32PI9 — 0.942 Q32PI9 →
O18796 — 0.941 O18796 →
Q9JK00 — 0.941 Q9JK00 →
Q9NY72 — 0.941 Q9NY72 →
Q9D806 — 0.940 Q9D806 →
Q9Z109 — 0.939 Q9Z109 →
Q8R5M8 — 0.939 Q8R5M8 →
P01861 — 0.938 P01861 →
Q9JKF6 — 0.937 Q9JKF6 →
P20917 — 0.936 P20917 →
Q3TEW6 — 0.936 Q3TEW6 →
Q2KI11 — 0.935 Q2KI11 →
P01860 — 0.935 P01860 →
Q14CZ8 — 0.935 Q14CZ8 →